Providing patients greater access to clinical trials and precision medicine through molecular tumor boards
In gynecologic oncology, molecular biomarkers are relatively limited, so molecular data are sometimes complex and are often interpreted on a case-by-case basis. The result may be delays in decision making or suboptimal treatment where patients may not have access to the growing number of new innovative drugs and clinical trials designed to treat cancers with specific genetic alterations.
Beginning in June 2021, MITO inaugurated a fully virtual, nationwide molecular tumor board using navify Tumor Board as the operational platform. This initiative includes about 40 MITO centers participating in the GYNGER observational trial (GYNecological cancers GEnetic profile Registry) and related specialists from oncology, gynecology, pathology, molecular biology, genetics and study coordinators of each center.
Using navify Tumor Board, 50 participating specialists who faced gynecological cancer patients are able to access, review and share anonymized clinical cases. The board’s final decision may include ranking of a molecular alteration and a matching drug using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), or patient referral to a bio-marker driven trial or expanded access program that is active in Italy. Finally, the patient is enrolled into the GYNGER study. In summary, navify Tumor Board is demonstrating its effectiveness at helping geographically dispersed multidisciplinary teams to collaborate more closely to deliver targeted and personalized patient care through expanded access to bio-marker specific treatment.
Molecular tumor boards can play a pivotal role in spreading new concepts of cancer genomics, flattening the learning curve of precision medicine.”
Prof. Sandro Pignata
Department of Urology and Gynecology Director, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy
References & notes
1 Pahwa, Sangeeta, and Arshdeep Kaur. “Statistical analysis of gynecological cancer.” International Journal of Reproduction, Contraception, Obstetrics and Gynecology, vol. 11, no. 1, Jan. 2022, pp. 130+. Gale Academic OneFile, link.gale.com/apps/doc/A690697383/AONE?u=anon~e374988c&sid=googleScholar&xid=eaf8d0d6. Accessed 26 Apr. 2022.
© 2023 Roche Molecular Systems, Inc.
NAVIFY is a trademark of Roche.
All other product names and trademarks are the property of their respective owners.
Not all products of this product portfolio are intended or approved for diagnostic use. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.